secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2024-12-12T23:59:59+00:00
Accession:  0001711279-24-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech reports positive initial clinical data for inhaled gene therapies KB408 (AATD) and KB407 (CF)
--------------------------------------------------------------------------------

- KB408: single dose increased lung AAT from 85nM to 729nM in AATD patient; active neutrophil elastase dropped >50%.
- Gene delivery confirmed: 39% of airway cells AAT-positive post-dose vs 0% at baseline.
- KB407 for CF: Phase 1 CORAL-1 granted conditional sanctioning by CFF TDN; safe and well tolerated.
- KB407 enrolling Cohort 3 (4 daily doses); data expected 1H 2025.
- No serious adverse events in either program; all adverse events mild to moderate and transient.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000062/0001711279-24-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127924000062/krys-20241212.htm
  HTML page:      https://secwatch.observer/filing/0001711279-24-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer